- The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in individuals aged 12 and above, the first approved therapy for this condition.
- EoE, characterized by chronic inflammation and the presence of eosinophils in the esophagus, commonly manifests in symptoms such as swallowing difficulties and food impaction.
- Researchers reported that Dupixent, a monoclonal antibody designed to target the inflammatory process, demonstrated effectiveness and safety in clinical trials, marking a significant breakthrough in EoE treatment.
In May 2022, the U.S. Food and Drug Administration
EoE is characterized by the presence of eosinophils, a specific type of white blood cell, in the esophageal tissue.
In adults and adolescents with EoE, common symptoms include difficulty swallowing, eating challenges, and food getting stuck in the esophagus.
Dupixent is a monoclonal antibody designed to inhibit a part of the inflammatory pathway.
Dr. Brooks Cash, a professor and chief of the division of Gastroenterology, Hepatology, and Nutrition at UTHealth Houston, told Medical News Today that “there are multiple different types of immune reactions that the body uses to protect itself depending on the target (for example viruses, parasites, bacteria, allergens).”
“In the case of EoE the type of immune response is called a type 2 immune response, which is the type of immune response directed toward allergens,” he explained.
“Other examples of this type of immune response include asthma, hives, allergic rhinitis, and certain food allergies,” Cash added.
“In the case of EoE, when the body is exposed to certain allergens, an immune cascade occurs that results in trafficking and…
Read the full article here